Experimental Pill Nearly Doubles Pancreatic Cancer Survival

A groundbreaking experimental pill has demonstrated the ability to nearly double survival time for patients with advanced pancreatic cancer, offering a long-awaited breakthrough against one of the deadliest forms of cancer. The drug, daraxonrasib (RMC-6236), targets the KRAS mutation present in more than 90% of pancreatic tumors — a protein that scientists had long considered “undruggable.”

Results from the Phase 3 RASolute-302 trial, published in the New England Journal of Medicine and presented Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago, showed that patients taking daraxonrasib lived for a median of 13.2 months compared to just 6.7 months for those receiving standard chemotherapy. The hazard ratio of 0.40 represents a 60% reduction in the risk of death.

A Turning Point for Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with a five-year survival rate of just 13%. Approximately 80% of patients are diagnosed at an advanced or metastatic stage, and treatment options after initial chemotherapy failure have been extremely limited. Historically, second-line therapies offered a median survival of only five to seven months.

“While not curing the cancer, it is a very large step forward,” said Dr. Zev Wainberg of the University of California, Los Angeles, who helped lead the study. The sentiment was echoed by Dr. Rachna Shroff of the University of Arizona Cancer Center, who told reporters she “actually started crying” when first seeing the results. “Patients stayed on this treatment because it was providing durable and meaningful benefit to them,” she said.

How Daraxonrasib Works

Developed by Revolution Medicines, a biotechnology company based in Redwood City, California, daraxonrasib employs a novel mechanism of action. Rather than targeting the inactive form of the RAS protein like earlier inhibitors, it binds to the active (GTP-bound) “ON” state using a molecular glue approach. The drug forms a tri-complex with RAS and Cyclophilin A (CypA), effectively blocking the cancer growth signals that drive tumor progression.

This approach is significant because it works across multiple KRAS mutation subtypes — including G12D, G12V, G12R, and G12C — making it relevant for the vast majority of pancreatic cancer patients. Previous KRAS inhibitors, such as sotorasib and adagrasib, only targeted the G12C mutation, which accounts for just 1-2% of pancreatic cancer cases.

Manageable Side Effects and Quality of Life

Importantly, patients on daraxonrasib experienced fewer severe side effects than those receiving chemotherapy. The most common adverse effects were rash, which can be severe in some cases, and mouth sores. Patients reported less pain and a better quality of life as their tumors shrank. Many participants remained on the drug even after the data was analyzed, suggesting the survival gap may widen as researchers continue tracking them.

Dr. Brian Wolpin of the Dana-Farber Cancer Institute, who presented the findings, said the drug should become “a new standard of care” for previously treated metastatic pancreatic cancer. Researchers are already planning studies to evaluate daraxonrasib in earlier stages of the disease, including whether tumor shrinkage might enable more patients to qualify for potentially curative surgery.

Regulatory Momentum and Patient Access

The U.S. Food and Drug Administration has granted daraxonrasib Breakthrough Therapy Designation and accepted it into a new expedited review process, signaling an accelerated path toward potential approval. Meanwhile, an expanded access (compassionate use) program began on May 1, 2026, allowing eligible patients to receive the drug free of charge before formal approval.

The drug garnered significant public attention when former U.S. Senator Ben Sasse, who is living with Stage 4 pancreatic cancer, described his experience on “60 Minutes,” noting he has experienced less pain while taking the medication. Oncologists across the country have reported being flooded with patient requests as the special access program gets underway.

What This Means for the Future

While daraxonrasib is not a cure — the drug’s effects eventually wane as resistance develops — it represents a paradigm shift in pancreatic cancer treatment. For the first time, a targeted therapy has demonstrated a substantial survival advantage over chemotherapy in the majority of PDAC patients.

“Doubling survival compared to best available chemotherapy is a big deal,” said Dr. Gulam Manji of Columbia/NY-Presbyterian. “It is not a cure, but I think that this drug is a new breakthrough we can build on.”

Dr. Julie Gralow, ASCO’s Chief Medical Officer, offered an even more emphatic assessment. “I have heard this study described as a home run,” she said. “I would actually say it is a grand slam.”

Looking ahead, Revolution Medicines has initiated the RASolute-303 trial evaluating daraxonrasib in newly diagnosed metastatic pancreatic cancer. Early data also suggests a 90% disease control rate when the drug is combined with standard chemotherapy regimens. Beyond pancreatic cancer, similar RAS(ON) inhibitors are being tested for lung and colon cancers, potentially expanding the impact of this breakthrough approach.

For the approximately 67,000 Americans diagnosed with pancreatic cancer each year — and the more than 52,000 who will die from it — daraxonrasib offers something that has been desperately needed: real, measurable hope.